Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
← catalyst calendarNCT04905693 · readout ≤ 1,230 d
Sponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,850estimated
Sites
192
Countries
Argentina, Australia, Belgium +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-06 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Progressive Pulmonary Fibrosis
Interventions
- Drug: Inhaled Treprostinil — also filed as Tyvaso
- Device: Treprostinil Ultrasonic Nebulizer
Primary outcome
what the primary-completion date above is the date OFLong-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF
measured Baseline to 6 years
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed